SECURITIES AND EXCHANGE COMMISSION

                            Washington, D. C.  20549

                                    FORM 10-Q


                 QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                    For the Quarter Ended September 29, 1996

                         Commission File Number 0-12948


                               CHEMFAB CORPORATION
             (Exact name of registrant as specified in its charter)


              Delaware                                 03-0221503
          (State or other jurisdiction of              (I.R.S. Employer
          incorporation or organization)               Identification No.)

          701 Daniel Webster Highway 
          Merrimack, New Hampshire                     03054
        (Address of principal executive office)        (Zip Code)


          Registrant's telephone number including
          area code:                                   (603) 424-9000


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed  by Section  13 or 15  (d) of  the Securities Exchange  Act of  1934
during  the preceding 12 months (or for  such shorter period that the registrant
was required to  file such reports),  and (2)  has been subject  to such  filing
requirements for the past 90 days.

                                   YES   X    NO
                                      ------    ------.      


Indicate  the number of  shares outstanding of  each of the  issuer's classes of
common stock, as of the latest practicable date.


                 Class                  Outstanding at October 28, 1996
     Common Stock, $ .10 par value           8,030,872 shares


                               CHEMFAB CORPORATION
                                      INDEX


Part I - Financial Information:                                    Page No.
                                                                   --------
   Item 1 -    Financial Statements
               --------------------

               Consolidated Balance Sheets at September             3  -  4  
               29, 1996 and June 30, 1996

               Consolidated Statements of Income for                   5  
               the Three Months Ended September 29,


               1996 and October 1, 1995            

               Consolidated Statements of Cash Flows                   6
               for the Three Months Ended September 
               29, 1996 and October 1, 1995

               Notes to Consolidated Financial Statements           7 -   8  

   Item 2 -    Management's Discussion and Analysis of              8 -  10 
               Financial Condition and Results of Operations
            
Part II - Other Information: 

   Item 6(a) - Exhibits                                                  10

   Item 6(b) - Reports on Form 8-K                                       10
                                              

   Signatures                                                            11


             PART I - FINANCIAL INFORMATION
             ------------------------------

                 CHEMFAB CORPORATION
             CONSOLIDATED BALANCE SHEETS



                                              Sept. 29,          June 30,
                                                1996              1996
                                            -----------       -----------  
                                            (Unaudited)
Current assets:
  Cash and cash equivalents                $  1,752,000      $  5,017,000
  Receivables:
    Trade                                    17,926,000        17,797,000
    Other                                       195,000           185,000
  Costs and estimated earnings in excess of 
    billings on uncompleted contra            1,125,000           886,000
  Inventories                                14,603,000        13,622,000
  Prepaid expenses, and other                 1,376,000         1,246,000
  Deferred tax assets                           762,000           795,000
                                            -----------        ----------

  Total current assets                       37,739,000        39,548,000

               
  Property, plant and equipment at cost      40,798,000        40,013,000
    Less accumulated depreciation
      and amortization                       20,209,000        19,473,000

  Net property, plant and equipment          20,589,000        20,540,000
                                            -----------       -----------

  Goodwill, net                              10,921,000        11,084,000
  Other assets                                2,599,000         2,490,000
                                            -----------       -----------

  Total assets                             $ 71,848,000      $ 73,662,000
                                            ===========       ===========
                                                                         

           See accompanying Notes to Consolidated Financial Statements

                                                                         


                 CHEMFAB CORPORATION
             CONSOLIDATED BALANCE SHEETS


                                              Sept. 29,          June 30,
                                                1996              1996
                                            -----------       -----------
                                            (Unaudited)
Current liabilities:
  Accounts payable and accrued
    expenses                               $  8,214,000      $  9,502,000
  Accrued income taxes                        1,862,000         1,441,000
  Billings in excess of costs and 
     estimated earnings on
     uncompleted contracts                      175,000           313,000
                                             ----------        ----------

  Total current liabilities                  10,251,000        11,256,000


Long - term debt                                 -              2,377,000
Deferred income taxes                         1,501,000         1,524,000

Shareholders' equity:
  Preferred stock, par value $.50:
     authorized - 1,000,000 shares,
     none issued                                   -                 -
  Common stock, par value $.10:
     authorized - 15,000,000 shares;
     issued - 8,204,513 at Sept, 29, 1996
     and 8,085,607 at June 30, 1996             820,000           809,000
  Additional paid-in capital                 19,521,000        18,314,000
  Retained earnings                          42,698,000        40,998,000
  Treasury stock, at cost,
     (205,904 shares at Sept. 29, 1996 
     and 95,938 at June 30,1996)             (2,393,000)         (943,000)
  Foreign currency translation
     adjustment                                (550,000)         (673,000)
                                             -----------       -----------

  Total shareholders' equity                 60,096,000        58,505,000

Total liabilities and shareholders'        $ 71,848,000      $ 73,662,000
                                           


           See accompanying Notes to Consolidated Financial Statements

                                           

                       

              CHEMFAB CORPORATION
        CONSOLIDATED STATEMENTS OF INCOME
                  (Unaudited)



                                           Three Months Ended     

                                      Sep. 29, 1996    Oct. 1, 1995
                                      -------------    ------------

Net sales                              $ 19,938,000    $ 18,466,000
Cost of sales                            13,191,000      12,567,000
                                      -------------    ------------

Gross Profit                              6,747,000       5,899,000
Selling, general and
  administrative expenses                 3,684,000       3,261,000
Research and development expenses           562,000         545,000
Other income                                (21,000)         (1,000)
Interest expense                             76,000         183,000 
Interest income                             (47,000)        (45,000)
                                      -------------    ------------

Income before income taxes                2,493,000       1,956,000

Provision for income taxes                  793,000         597,000
                                      -------------    ------------

Net income                             $  1,700,000     $ 1,359,000
                                      =============    ============

Weighted average common and
 common equivalent shares                 8,238,000       8,132,000
                                      =============    ============

Earnings per common share                     $0.21           $0.17
                                              =====           =====

  See accompanying Notes to Consolidated Financial Statements.
  


                      CHEMFAB CORPORATION
             CONSOLIDATED STATEMENTS OF CASH FLOWS
                          (Unaudited)

                                                         Three Months Ended
                                                
                                                Sept. 29, 1996     Oct. 1, 1995
                                                --------------     ------------

Cash flows from operating activities:

  Net income                                    $    1,700,000     $  1,359,000

  Adjustments to reconcile net income to net
    cash provided by operating activities:
      Depreciation and amortization                  1,062,000        1,039,000

      Change in assets and liabilities:
        Receivables                                    (95,000)       1,173,000
        Costs and estimated earnings in excess
          of billings on uncompleted contracts        (377,000)        (344,000)
        Inventories                                   (945,000)        (504,000)
        Prepaid expenses and other                    (128,000)        (318,000)
        Other assets long-term                        (193,000)         (98,000)
        Accounts payable and accrued expenses       (1,314,000)        (562,000)
        Accrued income taxes                           409,000         (901,000)
        Deferred tax assets and liabilities             10,000          (76,000)
                                                  ------------       ----------
        Total adjustments                           (1,571,000)        (591,000)
                                                  ------------       ---------- 

        Net cash provided by operating activities      129,000          768,000
                                             

Cash flows from investing activities:
  Capital expenditures (net)                          (761,000)        (555,000)
                                                  ------------       ----------

    Net cash used in investing activities             (761,000)        (555,000)



Cash flows from financing activities:
  Proceeds from exercise of stock options            1,219,000          365,000
  Repayment of long-term debt                       (2,382,000)      (1,067,000)
  Purchase of treasury shares                       (1,450,000)               0
                                                  ------------       ----------

    Net cash used in financing activities           (2,613,000)        (702,000)

Effect of exchange rate changes on cash                (20,000)         (11,000)
                                                  ------------       ----------

Net  decrease in cash and cash equivalents          (3,265,000)        (500,000)

Cash and cash equivalents at beginning of year       5,017,000        3,780,000
                                                  ------------       ----------

Cash and cash equivalents at end of period      $    1,752,000     $  3,280,000
                                                  ============       ==========

     
Interest paid                                   $      106,000     $    190,000
Income taxes paid                               $      152,000     $    936,000
                                                           


            See accompanying notes to the Consolidated Financial Statements




                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 The  consolidated  financial  statements  of  Chemfab   Corporation  (the
       Company) included  in this report reflect all  adjustments (consisting of
       only normally  recurring accruals) which,  in the opinion  of management,
       are  necessary for  a  fair presentation  of  the consolidated  financial
       position at  September 29, 1996  and June  30, 1996 and  the consolidated
       statements of income and cash flows for the  three months ended September
       29, 1996  and October 1, 1995.   The unaudited results  of operations for
       the interim periods reported are not necessarily indicative of results to
       be expected for the year.

       Certain notes and other  information have been condensed or  omitted from
       these interim financial statements.  The statements, therefore, should be
       read  in  conjunction  with  the consolidated  financial  statements  and
       related notes included in  the Chemfab Corporation Annual Report  on Form
       10-K for the year ended June 30, 1996 (file no. 0-12948).


Note 2 Inventories consist of the following:

                                   Sept. 29, 1996               June 30,1996
                                   --------------               ------------

            Finished Goods            $ 4,999,000                 $5,112,000
            Work in Process             3,779,000                  4,602,000
            Raw Materials               5,825,000                  3,908,000
                                       __________                 __________

                                      $14,603,000                $13,622,000
                                      ===========                ===========


 
Note 3 In  connection  with  obtaining  incentive  grants  from  the  Industrial
       Development  Authority of  Ireland  to subsidize  certain investments  in
       plant  and equipment in Ireland,  the Company's Irish subsidiary, Chemfab
       Europe,  has agreed  to  restrict repatriation  of  410,000  Irish
       pounds (U.S. $658,000) of  its retained earnings to fund repayment of the
       grants in the event of default  under the agreement.  Chemfab Corporation
       has also  provided  a parent  company  guarantee in  the event  that  the
       subsidiary's equity, so restricted, is not sufficient to repay any amount
       due.

       Various lawsuits and claims are pending or have been asserted against the
       Company, including  matters previously  disclosed by  the Company in  its
       form 10-K for the year ended June 30, 1996.  Although the outcome of such
       matters  cannot be predicted with  certainty and some  lawsuits or claims
       may  be disposed of unfavorably to the Company, management believes their
       disposition, to  the extent  not covered  by insurance,  will not have  a
       material adverse effect on the  Company's financial condition and results
       of operations.


Note 4 All reported share data has been adjusted to reflect the  Company's 3 for
       2 stock split in the form of a stock dividend in February 1996.


Note 5 Subsequent Event

       On  October 4, 1996, the Company entered  into a new three year revolving
       credit agreement jointly with two commercial banks, one based in the U.S.
       and the other in Ireland.  Under the terms of the agreement, the  Company
       has available a  $20,000,000 unsecured credit  facility until October  4,
       1999.   Thereafter, any balance outstanding will convert into a four year
       term loan with a five  year amortization schedule and a lump  sum payment
       due October  4, 2003.  Borrowing  under the facility is at  LIBOR plus 1%
       and the  Company is obligated  to pay a commitment  fee of 0.125%  of the
       unused portion  of the line.   The Company has  terminated its previously
       existing revolving credit agreement.


ITEM 2 Management's Discussion and Analysis of Financial Condition
       -----------------------------------------------------------
       and Results of Operations
       -------------------------


Three Months Ended September 29, 1996
-------------------------------------

Net Sales
---------

The  Company's consolidated net  sales for the three  months ended September 29,
1996,  the  first quarter  of  fiscal 1997,  increased  8%  to $19,938,000  from
$18,466,000 in  the  same  quarter  last  year.    Shipments  of  the  Company's
engineered products worldwide increased 14% over the year earlier period but 
were offset, in part, by a  decline in shipments of architectural products.  The
impact of changes in foreign currency exchange  rates on reported revenue growth
for the quarter was not material.

Engineered  Products -  Americas Business  Group sales  (which include  all non-
architectural product sales  to customers  in North America  and South  America)
increased 16%  to $9,843,000  from $8,462,000  for the  same quarter  last year.
This  sales  increase  resulted  principally  from  strength  in  the  Company's
aerospace,  communications,  energy  and  environment,  and general  distributor
markets.   It is expected that  revenues from sales of  engineered products into
the Americas will remain relatively strong through the end of the fiscal year.

Engineered Products -  European Business Group  sales   (which include all  non-
architectural  product sales to customers in  Europe, India, the Middle East and
Africa) increased  8% to  $6,142,000 from $5,665,000  in the  same quarter  last
year.  This increase in revenues  resulted principally from strength in sales to
general  distributors  throughout  Europe.   Moderate  growth  in  sales of  the
Company's  industrial products into these geographical areas, in line with first
quarter performance, is expected to continue through the end of the fiscal year.


Engineered Products -  Asia Pacific Business Group sales (which include all non-
architectural  product sales  to  customers  in  the  Far  East  and  Australia)
increased 23% to $1,294,000 from $1,052,000 in the same quarter last year.  This
increase  was  the result  of  a  strong marketing  and  sales  focus into  this
geographic area since the establishment of this business group approximately one
year ago.  Sales from the Company's newly established China  subsidiary were not
significant during the quarter, but are  expected to increase over the course of
the  year.  Percentage revenue growth from industrial product shipments into the
Asia Pacific region is expected to remain  strong through the end of the  fiscal
year.

Architectural Product sales decreased  19% to $2,659,000 from $3,287,000  in the
same  quarter last  year.   This decrease  in revenues  was expected and  is the
result of a lower number of  sizable projects  underway to-date this year versus
last  year.   The  Company expects  that  architectural  product sales  for  the
remainder of the year will be below the record levels achieved last year. 


Gross Profit Margins
--------------------


Gross  profit margins as a percentage of  consolidated net sales improved to 34%
for  the  quarter, up  from  32%  for  the first  quarter  of  last year.    The
improvement  is principally attributable  to the leveraging  effect of increased
revenues  on  a relatively  fixed  manufacturing  overhead  cost  structure  and
targeted cost reduction programs. 


Selling, Administrative, Research and Development Expenses
----------------------------------------------------------

Selling, general  and administrative expenses  increased 13% to  $3,684,000 from
$3,261,000  in  the same  quarter  last year.    Increased selling,  general and
administration expenditures  resulted from  the combined  effects of the  higher
cost  structure in place to  support the Company's  newly established subsidiary
operations in China  and Brazil (these were established after  the first quarter
of  last  year), as  well  as  normal increases  in  salaries  and other  costs.
Selling,  general and administrative expenses as  a percentage of sales was 18%,
the same as the first quarter of last year.

Research and development expenses were $562,000 compared to last year's level of
$545,000. This level of spending, at approximately 3% of total revenues, is 
consistent with recent, as well as planned, levels of research and development
spending.


Interest Expense, Net
---------------------

The Company had net interest expense of $29,000 for the quarter  compared to net
interest  expense of  $138,000 for the  same quarter  last year.   This decrease
resulted from  the repayment of debt  incurred to finance the  Tygaflor business
acquisition.


Liquidity and Capital Resources
-------------------------------

During the quarter ended September  29, 1996, the Company generated $129,000  of
cash from operations which was down from the same  quarter of the prior year due
to changes in working capital (on September 30, 1996, one day after the close of
the quarter, the Company collected a $2.8 million trade receivable).  During the
quarter,  the  Company  invested  $761,000  in  property,  plant  and  equipment
additions,  repaid  $2,382,000  of    long-term  debt  and  used  $1,450,000  to
repurchase stock under its share repurchase program.  The  Company also received
$1,219,000 in cash proceeds and related tax benefits from the  exercise of stock
options during this period.  

Working capital decreased  to $27,488,000 from $28,292,000 at the  end of fiscal
1996.  As of  September 29, 1996, the Company had  approximately $6.6 million of
credit  available  under its  domestic  and  international borrowing  facilities
(these  credit facilities have since  been replaced by  a new $20,000,000 credit
line - see Note  5 above) .    Management believes  that the combination of cash
on hand,  cash expected to  be generated  from operations, and  available credit
facilities, will be  adequate to finance  operations during  fiscal 1997 and  to
deal  with  any  liabilities  or  contingencies  described  in  Note  3  to  the
Consolidated Financial Statements.


Forward-Looking Statements
--------------------------

Except for the historical information contained herein, the matters discussed in
this form 10-Q  are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-
looking statements are inherently uncertain.  Actual performance and results may
differ  materially  from those  projected  or suggested  in  the forward-looking
statements due to certain risks and uncertainties including, without limitation,
the  timely introduction  of new  products and  the  market acceptance  of those
products,  and the  impact  of competitive  products  and pricing.    Additional
information  concerning certain risks and uncertainties  that could cause actual
results to differ materially from  those projected or suggested in the  forward-
looking statements is contained in the Company's filings with the Securities and
Exchange Commission,  including those risks  and uncertainties discussed  in the
Company's Annual Report on Form 10-K for the fiscal year ended  June 30, 1996 in
the  section   titled  "Forward-Looking  Statements".       The  forward-looking
statements contained herein represent  the Company's judgment as of the  date of
this  filing, and the  Company cautions readers  not to place  undue reliance on
such statements.



                           PART II - OTHER INFORMATION
                           ---------------------------

ITEM 6 - Exhibits and Reports on Form 8-K
         --------------------------------

     6(a) Exhibits
          --------
          10(b)(11) Consulting Agreement dated August 2, 1996, between Chemfab
          Corporation and Chemfab Director, Dr. Nicholas Pappas.

     6(b) Reports on Form 8-K
          -------------------
          None.  


                               CHEMFAB CORPORATION


                                   SIGNATURES
                                   ----------

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE
REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE
UNDERSIGNED THEREUNTO DULY AUTHORIZED.


              CHEMFAB CORPORATION
             -------------------
              (Registrant)




              by:/S/ Duane C. Montopoli                     
                 -------------------------------------------
              Duane C. Montopoli      
              President and Chief Executive Officer




              By:/S/Moosa E. Moosa                          
                 -------------------------------------------
              Moosa E. Moosa
              Vice President - Finance and Administration
              (Principal Financial Officer)




              by:/S/ Laurence E. Richard                   
                 ------------------------------------------
              Laurence E. Richard
              Controller
              (Principal Accounting Officer)




Date: November 12, 1996